MONITORING OF TNF-ALPHA BLOCKERS INFLIXIMAB AND ADALIMUMAB BY MEASURING TROUGH LEVEL CONCENTRATIONS AND ANTI-DRUG ANTIBODIES

被引：0
|
作者：
Westerlund, Johanna [1 ]
Jokiranta, T. Sakari [1 ,2 ]
机构：
[1] United Medix Labs Ltd, Espoo, Finland
[2] Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland
来源：
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2012年 / 41卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：325 / 325
页数：1
相关论文
共 50 条
  • [31] Measurement of functional blocade of TNF-alpha by anti-TNF G1 agents is a stronger predictor than trough levels and anti-drug antibodies: 3-year prospective clinical data
    Juillerat, Pascal
    Andrew, Peter
    Macpherson, James
    Slack, Emma
    Patuto, Nicola
    Cahenzli, Julia
    Schmid, Flavia
    Seibold, Frank
    McCoy, Kathy D.
    Macpherson, Andrew J.
    SWISS MEDICAL WEEKLY, 2015, 145 : S7 - S7
  • [32] Letter: predictive factors for treatment discontinuation in IBD-anti-TNF trough levels and anti-drug antibodies
    Demarzo, Maria Giulia
    Bodini, Giorgia
    Giuliana, Elisabetta
    Zentilin, Patrizia
    Giannini, Edoardo G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (04) : 536 - 537
  • [33] LOW DRUG CONCENTRATIONS AND ANTI-DRUG ANTIBODY FORMATION TO THE PRIOR ANTI-TNF PREDISPOSES PATIENTS WITH INFLAMMATORY BOWEL DISEASE TO DEVELOP ANTI-DRUG ANTIBODIES TO THE SUBSEQUENT ANTI-TNF
    Cheifetz, Adam S.
    Abreu, Maria T.
    Flier, Sarah N.
    Papamichail, Konstantinos
    Rieder, Florian
    Silverberg, Mark S.
    Khanna, Reena
    Okada, Lauren
    Yang, Lei
    Jain, Anjali
    Vande Casteele, Niels
    GASTROENTEROLOGY, 2020, 158 (06) : S457 - S457
  • [34] The early appearance of anti-drug antibodies during the induction phase predicts the clinical response of adalimumab and infliximab in IBD
    Roblin, X.
    Williet, N.
    Veyrard, P.
    Boschetti, G.
    Berger, A. E.
    Nancey, S.
    Flourie, B.
    Paul, S.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S369 - S369
  • [35] Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis
    Quistrebert, Jocelyn
    Hassler, Signe
    Bachelet, Delphine
    Mbogning, Cyprien
    Musters, Anne
    Tak, Paul Peter
    Wijbrandts, Carla Ann
    Herenius, Marieke
    Bergstra, Sytske Anne
    Akdemir, Gulsah
    Johannesson, Martina
    Combe, Bernard
    Fautrel, Bruno
    Chollet-Martin, Sylvie
    Gleizes, Aude
    Donnellan, Naoimh
    Deisenhammer, Florian
    Davidson, Julie
    Hincelin-Mery, Agnes
    Donnes, Pierre
    Fogdell-Hahn, Anna
    De Vries, Niek
    Huizinga, Tom
    Abugessaisa, Imad
    Saevarsdottir, Saedis
    Hacein-Bey-Abina, Salima
    Pallardy, Marc
    Broet, Philippe
    Mariette, Xavier
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 48 (06) : 967 - 975
  • [36] Serum trough infliximab and anti-infliximab antibodies in a cohort of gastroenterology and rheumatology patients' infliximab therapeutic drug monitoring
    Barlow, Nicola L.
    Mohammed, Pervaz
    Berg, Jonathan D.
    ANNALS OF CLINICAL BIOCHEMISTRY, 2016, 53 (04) : 477 - 484
  • [37] THE EARLY APPEARANCE OF ANTI-DRUG ANTIBODIES DURING THE INDUCTION PHASE PREDICTS THE CLINICAL RESPONSE OF ADALIMUMAB AND INFLIXIMAB IN IBD
    Roblin, Xavier
    Williet, Nicolas
    Flourie, Bernard
    Berger, Anne
    Ben-Horin, Shomron
    Paul, Stephane
    GASTROENTEROLOGY, 2020, 158 (06) : S47 - S47
  • [38] Detection of infliximab, adalimumab, and anti-drug antibodies: Development and validation of new monotest, automated assays on multiparametric instrument
    Cerutti, Helena
    Tesi, Giulia
    Petrini, Francesco
    Bandini, Tommaso
    Cartocci, Alessandra
    Ianniello, Andrea
    Bogi, Alessia
    Muzzi, Chiara
    Brogi, Alessandra
    PRACTICAL LABORATORY MEDICINE, 2024, 39
  • [39] INFLIXIMAB TROUGH LEVELS AND ANTI-DRUG ANTIBODIES AFTER INDUCTION AS PREDICTIVE FACTORS OF LONG TERM CLINICAL REMISSION
    Bodini, G.
    Del Nero, L.
    Giannini, E.
    De Maria, C.
    Baldissarro, I
    Savarino, V
    Savarino, E.
    DIGESTIVE AND LIVER DISEASE, 2016, 48 : E163 - E163
  • [40] Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis
    Mori, Ayano
    Saito, Toshiharu
    Takahashi, Miho
    Shibata, Miho
    Tsuji, Goh
    Hatachi, Saori
    Takahashi, Soshi
    Kumagai, Shunichi
    PLOS ONE, 2020, 15 (12):
12345